TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06704100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir Calcium & Sodium Alginate
Description: 1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate
Study: NCT06715566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActForStroke
Description: ActForStroke is a combination of 10 sessions high-intensity gait training and subsequent with up 7 coaching sessions until 1 year after stroke.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual rehabilitation services
Study: NCT06716853

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg IV every 6 weeks commencing at D+30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40mg QD once PD occurs as assessed at D+30 or at subsequent visits
Study: NCT06718062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren
Description: Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20138002. The primary objective is to evaluate the non-inferiority of Aliskiren in lowering serum uric acid levels, and its effects on blood pressure and kidney function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20143030. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
Study: NCT06717529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (hyaluronic acid)
Description: The patient will receive one 3mL Sodium Hyaluronate injection containing 75 mg of active substance in one knee joint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate Injection
Description: The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
Study: NCT06714760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction following parcellar resections of the mandibular gingival region
Description: In our surgical approach, we have used periosteum, galea, or pericranium flaps for reconstruction of bone and tissue defects in the cervicofacial region, with excellent results. To treat mandibular osteoradionecrosis, we harvested periosteum flaps from the radius, demonstrating efficacy in bone regeneration. For minor defects, such as those of the nose, we used flaps from the medial femoral condyle, despite the complexity of harvesting.~The cranial region, particularly the temporo-parietal area, offered excellent vascularization, allowing the use of revascularized flaps for reconstruction of the oral mucosa after removal of carcinomas. These flaps have also been effective in the treatment of pharyngeal fistulas, proving to be a functionally reliable solution for oral cavity and cervicofacial defects.
Study: NCT06716905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT500 tablets
Description: Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to ACT500 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT500 tablets
Description: Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to ACT500 Tablets.
Study: NCT06716801

Intervention type: DRUG
Intervention: Cenobamate
Description: Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications.
Study: NCT06718257

Intervention type: DRUG
Intervention: Gemcitabine combined with cisplatin or oxaliplatin
Description: Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)

Intervention type: DRUG
Intervention: Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
Description: Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
Study: NCT06715059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation exercise program
Description: A progressive core stability exercise program will be performed based on motor control principles via an online platform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: A core stability exercise program will be performed at home.
Study: NCT06716268

Intervention type: OTHER
Intervention: phonation and respiratory tasks
Description: Participants performed various tasks to evaluate pelvic floor muscle activity and displacement. These included a maximum voluntary contraction (cutting off the flow of urine mid-stream), a pelvic floor strain (bearing down for a bowel movement), and the Valsalva maneuver to clear the Eustachian tubes. Additionally, phonation and respiratory exercises were conducted, such as producing the ah sound at different pitches, open-mouth exhalation, coughing, and semi-occluded vocal tract (SOVT) exercises using a small coffee straw, commonly used in singing warm-ups to enhance vocal efficiency. Each task lasted 3 seconds, with 1-minute rest intervals to assess their impact on pelvic floor displacement
Study: NCT06714825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS235
Description: Up to 4 Single and 3 Multiple Ascending Doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT06715410

Intervention type: DEVICE
Group type: OTHER
Intervention: CO2
Description: To collect CO2 data
Study: NCT06717308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort Release® NPWT drape
Description: Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort Release® NPWT drape
Description: Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.
Study: NCT06717945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam besylate
Description: Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
Study: NCT06717087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture+lifestyle intervention
Description: 8 weeks Acupuncture treatment for 2-3 times/week, 30min each time and lifestyle intervention((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin+lifestyle intervention
Description: 8 weeks Metformin 500 mg three times a day with meals and lifestyle intervention ((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
Study: NCT05608148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 with nivolumab combination
Study: NCT05058898

Intervention type: OTHER
Intervention: blood samples
Description: 5 mL

Intervention type: OTHER
Intervention: blood samples
Description: 5 mL

Intervention type: OTHER
Intervention: blood samples
Description: 5 mL

Intervention type: OTHER
Intervention: blood samples
Description: 5 mL

Intervention type: OTHER
Intervention: Scabs and pus samples
Description: if available

Intervention type: OTHER
Intervention: Scabs and pus samples
Description: if available
Study: NCT05202223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony at HOME (H@H)
Description: H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
Study: NCT06051136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation.
Study: NCT05360823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth ball
Description: Exercises for childbirth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squatting
Description: Exercises for childbirth
Study: NCT04826237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Oral dose to be taken with methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: oral dose, standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: oral dose, standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Drug for intratympanic administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Drug for intratympanic administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule the same as for statins but without statin
Study: NCT04691388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab combined with anlotinib
Description: All patients will receive sintilimab combined with anlotinib every 3 weeks
Study: NCT06159504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir/velpatasvir (SOF/VEL)
Description: 400mg of SOF and 100mg of VEL self administered daily as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir (SOF/VEL)
Description: 400mg of SOF and 100mg of VEL self administered daily as a tablet.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shortened read time of rapid diagnostic test for hepatitis C virus.
Description: Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
Study: NCT05627700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVL200 IOL
Description: The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
Study: NCT06022094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 months of reduced carb menus
Description: Participants will eat a reduced carb menu for 2 months
Study: NCT05367869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy
Description: General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
Study: NCT06042426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Two 8 mg doses. One dose applied prior to incision and the other at POD1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 0.1 mg per kg intravenous every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and acetaminophen
Description: 2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
Study: NCT06557629

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment
Description: Ultrasound assessment of gastric residual volume
Study: NCT06005480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Injection of 1.5% Mepivacaine in nerve block
Study: NCT06210607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10511 Tablets
Description: HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10511 Tablets Placebo
Description: HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
Study: NCT06262516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Participants will undergo standard-of-care nephroureterectomy for UTUC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephroureterectomy
Description: Participants will undergo standard-of-care nephroureterectomy for UTUC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Dissection
Description: Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
Study: NCT05412992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS Patch
Description: DMTS applied before surgery and worn for 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study: NCT05390164

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: skin biopsy to be analyzed by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: skin biopsy to be analyzed by ELISA
Study: NCT04895371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-physiotherapy group
Description: Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
Study: NCT05439733

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Women will be asked to complete questionnaires 6 weeks after delivery

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Women will be asked to complete questionnaires 6 weeks after delivery
Study: NCT05575284

Intervention type: PROCEDURE
Intervention: Robot-assisted urological surgery
Description: Patient with programmed robot-assisted urological surgery
Study: NCT04511780

Intervention type: OTHER
Intervention: questionnaire filling
Description: assessment of post-traumatic stress, anxiety and burn out
Study: NCT05747755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADEPT Program
Description: Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
Study: NCT05253365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
Study: NCT06285630

Intervention type: OTHER
Intervention: Observational, no intervation will be made
Description: No intervention will be made, only longitudinal sample collection.
Study: NCT05384717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fidget Device
Description: Fidget spinner, stress ball, pop-it, or fidget cube

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention
Study: NCT04489758

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis
Description: Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis
Description: Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
Study: NCT06223217

Intervention type: OTHER
Intervention: Surveys and Questionnaires
Description: The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
Study: NCT04879654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
Study: NCT05228171

Intervention type: BEHAVIORAL
Intervention: mCC app
Description: Interviewer use of the mCC app during the 24-hour dietary recall interview.
Study: NCT06082492

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
Study: NCT06236672

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: GLP-1 RA initiated between January 2019 and December 2022

Intervention type: DRUG
Intervention: basal insulin
Description: basal insulin initiated between January 2019 and December 2022